SRL to market Rosetta's miRview diagnostic tests in India, Saudi Arabia, Qatar & UAE

Rosetta Genomics, Ltd, a leading developer of microRNA-based molecular diagnostics, and Super Religare Laboratories Limited (SRL), India's largest diagnostics network, have signed an exclusive distribution agreement for Rosetta Genomics' three currently-available diagnostic tests. 

Under the terms of the agreement, SRL will market Rosetta Genomics' miRview tests in India, Saudi Arabia, Qatar, and the UAE. Samples will be sent from SRL's territories to Rosetta Genomics' Philadelphia-based CLIA-certified laboratory for analysis. 

The agreement between Rosetta and SRL also envisages joint cooperation and collaboration between the two companies to conduct field trials for development of tests and assays an exchange of information for development of new technologies and leading edge diagnostic solutions.

The Rosetta Genomics tests that will be distributed by SRL in India include miRview mets (to accurately identify the primary tumour site in patients with metastatic cancer); miRview squamous (this differentiates squamous from non-squamous, non-small cell lung cancer (NSCLC) patients) and miRview meso (to differentiate mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung). 

Comments

Popular posts from this blog

GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut

Trump wants more mental health care; Alabama says it's trying